Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Articles

Page Path
HOME > Diabetes Metab J > Volume 35(3); 2011 > Article
Original Article
Relationship between Chemerin Levels and Cardiometabolic Parameters and Degree of Coronary Stenosis in Korean Patients with Coronary Artery Disease
Yu-Jin Hah, Nam-Keong Kim, Mi-Kyung Kim, Hye-Soon Kim, Seung-Ho Hur, Hyuck-Jun Yoon, Yoon-Nyun Kim, Keun-Gyu Park
Diabetes & Metabolism Journal 2011;35(3):248-254.
DOI: https://doi.org/10.4093/dmj.2011.35.3.248
Published online: June 30, 2011
  • 24,613 Views
  • 30 Download
  • 40 Crossref
  • 48 Scopus

Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.

Corresponding author: Keun-Gyu Park. Department of Internal Medicine, Keimyung University School of Medicine, 194 Dongsan-dong, Jung-gu, Daegu 700-712, Korea. kgpark@dsmc.or.kr
*Yu-Jin Hah and Nam-Keong Kim contributed equally to this study as first authors.
• Received: May 31, 2010   • Accepted: December 14, 2010

Copyright © 2011 Korean Diabetes Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • Background
    Chemerin is a novel adipokine that is associated with inflammation and adipogenesis. However, it remains unclear whether chemerin is involved in patients with cardiovascular disease. We investigated whether the serum chemerin levels of Korean patients with coronary artery disease correlated with specific cardiometabolic parameters.
  • Methods
    In total, 131 patients, all of whom had coronary artery stenosis exceeding 50%, participated in this study. Their serum chemerin levels and cardiometabolic parameters were measured. The serum chemerin levels of two groups of patients were compared; those with one stenotic vessel (n=68) and those with multiple stenotic vessels, including left main coronary artery disease (n=63).
  • Results
    Serum chemerin levels correlated positively with the degree of coronary artery stenosis and fasting glucose, triglyceride, total cholesterol, low density lipoprotein cholesterol, and high sensitive C-reactive protein levels. The group with multiple stenotic vessels, including left main disease, had higher chemerin levels than the group with one stenotic vessel (t=-2.129, P=0.035). Multiple binary logistic regression showed chemerin was not an independent risk factor of multiple vessel disease (odds ratio, 1.018; confidence interval, 0.997 to 1.040; P=0.091).
  • Conclusion
    Serum chemerin levels have a significant correlation with several cardiometabolic risk factors and the degree of coronary artery stenosis in Korean patients with coronary artery disease. However, multiple binary logistic regression showed chemerin was not an independent risk factor of multiple vessel disease. Additional investigations are necessary to fully elucidate the role of chemerin in cardiovascular disease.
Due to the essential role obesity plays in the pathogenesis of metabolic syndrome, a syndrome that is associated with cardiovascular morbidity, considerable interest has arisen in understanding the role obesity plays in cardiovascular disease [1]. Adipose tissue is no longer thought to only store excess energy; rather, it appears to be an active endocrine organ that produces many cytokines, which are known as adipokines [2-6]. These adipokines appear to have systemic effects on the brain, liver, muscles, β-cells, gonads, lymphoid organs, and vasculature [7]. Many studies have examined the role adipose tissue plays in the development of coronary artery disease in patients with metabolic syndrome [8-13], and it is now understood that adipose tissue can cause vascular complications either directly by causing atherosclerosis and inducing inflammatory responses, or indirectly by promoting the development of insulin resistance [14]. These atherosclerosis-inducing pathways are mediated by various adipokines, including adiponectin, leptin, retinol binding protein-4 and resistin [8-12]. Analyses of additional adipokines may help us to further understand the pathogenesis of insulin resistance and its cardiovascular complications.
Chemerin is a recently discovered 16 kDa chemoattractant protein that acts as a ligand for the G-protein receptor CMKLR1 (ChemR23 or DEZ) [15,16]. It is secreted by adipose tissue as prochemerin (18 kDa) [16] and is transformed into an active protein by serine protease cleavage of its C-terminal fragment [17]. In its active form, chemerin regulates the immune system and participates in inflammation by promoting the recruitment of tissue macrophages and plasmacytoid dendritic cells [15,18]. Chemerin is also associated with adipogenesis, as studies with Psammomys obesus have shown that while both chemerin and CMKLR1 are expressed by all tissues, their expression is particularly high in the liver, kidney, and adipose tissue [19]. Moreover, while undifferentiated adipose tissue only expresses low levels of chemerin and CMKLR1, both molecules are expressed at progressively higher levels by differentiated adipocytes [15]. The knockdown of chemerin or CMKLR1 expression in pre-adipocytes severely impairs their differentiation and reduces the expression of genes involved in glucose and lipid metabolism [15]. These observations suggest that chemerin may participate in insulin resistance and its cardiovascular complications.
As mentioned above, chemerin is associated with inflammation, adipogenesis, glucose, and lipid metabolism, all of which may contribute to the development of diabetic cardiovascular complications, especially atherosclerosis [15,18,19]. Therefore, we hypothesized that chemerin levels might be related to other cardiometabolic markers and that an increase in chemerin might reflect the degree of atherosclerotic burden. To further address this question, we examined whether the chemerin levels in Korean patients with coronary artery disease correlate with specific cardiometabolic parameters.
Subjects
Of the patients who underwent coronary angiography at Keimyung University Dongsan Hospital, Daegu, Korea from November 2006 to April 2007, 131 were proven by coronary angiography to have meaningful stenosis (≥50%) and were recruited. Patients who did not have infections or renal or liver failure were eligible for the study. The medical history of each patient was determined by a questionnaire. The present study was approved by the local Ethical Review Committee of the Keimyung University School of Medicine. All participants gave informed consent.
Anthropometric, blood pressure, and biochemical measurements
All patients provided their personal information, and their height, weight, and waist circumference were measured. Body mass index (BMI) was calculated (kg/m2). Blood pressure was measured by an electronic device (FA-94H; Fanics, Korea) after sitting for 5 minutes. Blood was drawn in the morning after a 12-hour fast. The fasting serum glucose levels were measured by using the glucose oxidase method (Cobas Integra 800; Roche, Basel, Switzerland). Fasting serum insulin concentrations were measured by a radioimmunoassay kit (Insulin Myria; TechnoGenetics, Milano, Italy). The homeostasis model of assessment of insulin resistance (HOMA-IR) was calculated as fasting insulin×(fasting glucose/22.5). The levels of the following biochemical markers were measured by enzymatic methods (Cobas Integra 800): serum triglyceride, total cholesterol, and high density lipoprotein (HDL) and low density lipoprotein (LDL) cholesterol. High sensitive C-reactive protein (hsCRP) concentrations were measured using the latex method (TBA-200FR; Tosiba, Tokyo, Japan). Serum homocysteine concentrations were measured using an Axsym (Abbott, Abbott Park, IL, USA). The separated sera were stored at -70℃ until the chemerin levels could be measured using a commercially available ELISA (R&D, Minneapolis, MN, USA) as previously described [19]. The capture antibody and detection antibody were used. Intra- and inter-assay coefficients of variance for the chemerin ELISA were 5.0% and 10.0%, respectively. The sensitivity of the ELISA assay was 1 to 10 ng/dL, and the midrange of the assay was 5 ng/dL. This kit can detect human chemerin concentration by 0.5 ng/dL at least.
Coronary angiogram
Angiographic images were reviewed by an experienced cardiologist who was unaware of the patient's biochemistry results. As outlined in the Duke coronary artery index [20,21], we defined significant stenosis as >50% of the lumen diameter. The degree of stenosis of the diseased vessels served as a severity index. Patients were divided into two groups; those with one stenotic vessel (n=68) and those with multiple stenotic vessels, including left main disease (n=63).
Statistical analysis
The data are expressed as mean±standard deviation. We performed Student's t-test to compare chemerin levels and other metabolic factors in patients divided according to the number of stenotic vessels, and checked multiple binary logistic regression analysis (95% confidence interval) on risk of multiple vessel stenosis. We performed Pearson's correlation analyses between chemerin and cardiometabolic factors using SPSS version 12.0 software for Windows (SPSS Inc., Chicago, IL, USA). P values of less than 0.05 were considered statistically significant.
Clinical and metabolic subject characteristics
Table 1 shows the clinical characteristics of the 131 study subjects, of whom 86 (65.6%) and 45 (33.6%) were men and women, respectively. In total, 69 (52.7%) patients were smokers, 32 (24.4%) had diabetes and 85 (64.9%) had hypertension. Mean BMI was 24.1±2.8 kg/m2. Thirty-five (26.7%) patients were overweight (BMI 23 to 24.9 kg/m2) and 51 (39.0%) patients were obese (BMI >25 kg/m2). Angiography showed that 68 (49.8%) patients had one vessel disease, 39 (32.2%) had two vessel disease, 16 (12.3%) had triple vessel disease, and 8 (5.8%) had left main disease. In addition, 84 (64.1%) patients were being treated with anti-platelet agents, 32 (24.4%) patients were being treated with an oral hypoglycemic agent, 85 (64.9%) patients were being treated with an antihypertensive drug, and 48 (36.7%) patients were being treated with statins before enrollment.
Correlation between serum chemerin concentrations and cardiometabolic parameters
There were significant but weak correlations between serum chemerin concentrations and fasting glucose, triglyceride, total cholesterol, LDL-cholesterol and hsCRP (Table 2). However, serum chemerin concentrations did not correlate significantly with fasting insulin, HDL-cholesterol or homocysteine levels, BMI, waist circumference, HOMA-IR and systolic and diastolic blood pressure.
Correlation between serum chemerin concentrations and coronary angiographic findings
To determine whether serum chemerin concentration is associated with coronary artery disease, we analyzed the correlation between serum chemerin concentrations and coronary stenosis (%) in all participants. Fig. 1 shows how serum chemerin concentrations correlate with the degree of coronary artery stenosis. We measured a significant positive correlation, albeit weak, between these two parameters (r=0.0200, P=0.022). Moreover, the group with multiple vessel disease, including left main disease, showed higher age and chemerin, LDL, and CRP levels than the one vessel disease group (Table 3). However, Table 4 depicts that chemerin level is not an independent risk factor in multiple vessel disease.
Accumulating evidence has suggested that adipokines play an important role in the development of coronary artery disease in patients with metabolic syndrome [8-13]. Recent studies have shown that chemerin levels associate significantly with metabolic components of the metabolic syndrome [19,22,23]. However, whether chemerin levels are also associated with cardiovascular parameters in patients with coronary artery disease remains to be elucidated. In this study, we investigated whether circulating chemerin concentrations correlate with the cardiometabolic parameters of Korean patients with coronary artery disease. We observed that serum chemerin concentrations were positively correlated with fasting glucose, triglyceride, total cholesterol, LDL-cholesterol, and hsCRP. Serum chemerin concentrations also had a significant correlation with the degree of coronary artery stenosis, although we recognize this association was weak.
Chemerin is a recently identified chemoattractant protein that induces leukocyte migration; in addition, its receptor is expressed by tissue macrophages [16-18]. These observations suggest that chemerin functions in the development of inflammatory diseases, including atherosclerosis. In this study, we found that chemerin levels correlated positively with hsCRP levels. hsCRP is a circulating marker of inflammation that is predominantly produced by the liver in response to IL-6 [24]. Patients with metabolic syndrome have higher CRP levels than healthy individuals, and this high CRP level is an independent risk factor for type 2 diabetes and cardiovascular disease [24-26]. CRP also directly promotes the inflammatory component of atherosclerosis by inducing adhesion molecule expression by human endothelial cells [27]. Recently, Lehrke et al. [22] analyzed the relationship between chemerin and metabolic components in patients with chest pain. In their study, chemerin is associated with coronary plaque burden and the number of non-calcified plaques, but these correlations dropped out after adjusting for other cardiovascular risk factors. In contrast to their study, this report shows that there was a significant but weak correlation between chemerin concentrations and the degree of coronary artery stenosis even after adjusting for other factors. Moreover, the group with multiple vessel disease had higher chemerin levels than the group with one vessel disease. Thus, our study suggests the possibility that chemerin could be associated with coronary artery disease; however our study did not show that chemerin level was not an independent risk factor in multiple vessel disease.
In addition to having pro-inflammatory effects, chemerin is a novel adipokine that has been associated with metabolic syndrome phenotypes [22]. Chemerin has been shown to regulate adipocyte differentiation and the expression of adipocyte genes involved in glucose and lipid homeostasis [19]. While Bozaoglu et al. [19] previously failed to detect a significant difference in the chemerin levels of subjects with normal glucose tolerance and subjects with type 2 diabetes, obese subjects were found to have significantly higher chemerin levels than lean subjects. Moreover, the chemerin levels in normal glucose-tolerant subjects were found to correlate significantly with various metabolic parameters, including BMI, waist circumference, waist-hip ratio, fasting glucose levels, fasting insulin levels, plasma triglyceride levels, and blood pressure [19]. However, this study shows that while serum chemerin concentrations significantly but weakly correlated with fasting glucose, triglyceride, total cholesterol and LDL cholesterol levels, they did not correlate with fasting insulin levels, HOMA-IR, BMI, waist circumference or blood pressure. This discrepancy may be due to differences between the study populations of the previous study and our own. In particular, our study included subjects who were taking antihypertensives, oral hypoglycemia agents and statins.
This study has certain limitations that we will address here. First, we measured the number of significant coronary stenoses without individualizing each coronary stenosis according to the type of lesion involved. If we had done so, we could have obtained a more accurate correlation between chemerin and coronary stenosis (%). Second, we enrolled patients with significant coronary artery stenosis (mentioned in Methods; >50% of patients) without enrolling healthy controls with no coronary artery disease. Thus, we could not determine the odds ratio of various cardiometabolic factors in coronary atherosclerosis. Third, the chemerin ELISA kit used in this study measures full-length chemerin form. Chemerin protein exists as a full-length protein in plasma, but this form of the protein is known to have lower bioactivity than prochemerin [28]. However, despite these shortcomings, the results suggest that chemerin could be useful as a predictor of metabolic syndrome and cardiovascular complications.
In conclusion, we found that circulating chemerin concentrations weakly but significantly correlated with several cardiometabolic parameters as well as the severity of coronary artery stenosis in Korean patients with coronary artery disease. However, multivariate analysis showed chemerin was not an independent risk factor for multiple vessel disease. Additional investigations are necessary to fully elucidate the role chemerin plays in the development and/or progression of cardiovascular disease.
Acknowledgements
This study was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (A08-4335-AA2004-08N1-00020B).

No potential conflict of interest relevant to this article was reported.

  • 1. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968-977. ArticlePubMed
  • 2. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006;55:1537-1545. PubMed
  • 3. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004;92:347-355. ArticlePubMed
  • 4. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006;17:4-12. PubMed
  • 5. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008;34:2-11. ArticlePubMed
  • 6. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000;11:327-332. ArticlePubMed
  • 7. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000;106:473-481. ArticlePubMedPMC
  • 8. Steffens S, Mach F. Adiponectin and adaptive immunity: linking the bridge from obesity to atherogenesis. Circ Res 2008;102:140-142. PubMed
  • 9. Nakamura Y, Shimada K, Fukuda D, Shimada Y, Ehara S, Hirose M, Kataoka T, Kamimori K, Shimodozono S, Kobayashi Y, Yoshiyama M, Takeuchi K, Yoshikawa J. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart 2004;90:528-533. ArticlePubMedPMC
  • 10. Parhami F, Tintut Y, Ballard A, Fogelman AM, Demer LL. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res 2001;88:954-960. PubMed
  • 11. Ingelsson E, Sundstrom J, Melhus H, Michaelsson K, Berne C, Vasan RS, Riserus U, Blomhoff R, Lind L, Arnlov J. Circulating retinol-binding protein 4, cardiovascular risk factors and prevalent cardiovascular disease in elderly. Atherosclerosis 2009;206:239-244. ArticlePubMed
  • 12. Pischon T, Bamberger CM, Kratzsch J, Zyriax BC, Algenstaedt P, Boeing H, Windler E. Association of plasma resistin levels with coronary heart disease in women. Obes Res 2005;13:1764-1771. ArticlePubMed
  • 13. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 2005;288:H2031-H2041. ArticlePubMed
  • 14. Kowalska I. Role of adipose tissue in the development of vascular complications in type 2 diabetes mellitus. Diabetes Res Clin Pract 2007;78(Suppl 1):S14-S22.Article
  • 15. Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, Muruganandan S, Sinal CJ. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007;282:28175-28188. ArticlePubMed
  • 16. Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le Poul E, Migeotte I, Brezillon S, Tyldesley R, Blanpain C, Detheux M, Mantovani A, Sozzani S, Vassart G, Parmentier M, Communi D. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003;198:977-985. ArticlePubMedPMCPDF
  • 17. Zabel BA, Allen SJ, Kulig P, Allen JA, Cichy J, Handel TM, Butcher EC. Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J Biol Chem 2005;280:34661-34666. ArticlePubMed
  • 18. Zabel BA, Silverio AM, Butcher EC. Chemokine-like receptor 1 expression and chemerin-directed chemotaxis distinguish plasmacytoid from myeloid dendritic cells in human blood. J Immunol 2005;174:244-251. ArticlePubMedPDF
  • 19. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, Walder K, Segal D. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007;148:4687-4694. ArticlePubMedPDF
  • 20. Mark DB, Nelson CI, Califf RM, Harrell FE Jr, Lee KL, Jones RH, Fortin DF, Stack RS, Glower DD, Smith LR, DeLong ER, Smith PD, Reves JG, Jollis JG, Tcheng JE, Muhlbaier LH, Lowe JE, Phillips HR, Pryor DB. Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. Circulation 1994;89:2015-2025. ArticlePubMed
  • 21. Miller JM, Rochitte CE, Dewey M, Arbab-Zadeh A, Niinuma H, Gottlieb I, Paul N, Clouse ME, Shapiro EP, Hoe J, Lardo AC, Bush DE, de Roos A, Cox C, Brinker J, Lima JA. Diagnostic performance of coronary angiography by 64-row CT. N Engl J Med 2008;359:2324-2336. ArticlePubMed
  • 22. Lehrke M, Becker A, Greif M, Stark R, Laubender RP, von Ziegler F, Lebherz C, Tittus J, Reiser M, Becker C, Goke B, Leber AW, Parhofer KG, Broedl UC. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol 2009;161:339-344. ArticlePubMed
  • 23. Tan BK, Chen J, Farhatullah S, Adya R, Kaur J, Heutling D, Lewandowski KC, O'Hare JP, Lehnert H, Randeva HS. Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes 2009;58:1971-1977. ArticlePubMedPMCPDF
  • 24. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805-1812. ArticlePubMedPMC
  • 25. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-369. ArticlePubMed
  • 26. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843. ArticlePubMed
  • 27. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-2168. ArticlePubMed
  • 28. Yoshimura T, Oppenheim JJ. Chemerin reveals its chimeric nature. J Exp Med 2008;205:2187-2190. ArticlePubMedPMCPDF
Fig. 1
Correlation between chemerin levels and the degree of coronary artery stenosis. Pearson's correlation coefficient=0.21; P<0.022.
dmj-35-248-g001.jpg
Table 1
Clinical and metabolic characteristics of subjects
dmj-35-248-i001.jpg

Data are presented as mean±standard deviation or number (%).

BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein; HOMA-IR, homeostasis model of assessment of insulin resistance; hsCRP, high sensitive C-reactive protein; SBP, systolic blood pressure; DBP, diastolic blood pressure; Stenosis (%), percentage of coronary artery stenosis.

Table 2
Correlation between chemerin and cardiometabolic parameters
dmj-35-248-i002.jpg

The P values are from Pearson's correlations.

BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein; HOMA-IR, homeostasis model of assessment of insulin resistance; hsCRP, high sensitive C-reactive protein; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Table 3
Characteristics in patients divided according to the number of stenotic vessels and presence of left main lesions
dmj-35-248-i003.jpg

Data are presented as mean±standard deviation.

Patients were divided according to one stenotic vessel (one vessel disease) or multiple stenotic vessels (multiple vessel disease).

The P values are from Student's t-test.

BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein; HOMA, homeostasis model of assessment; hsCRP, high sensitive C-reactive protein; SBP, systolic blood pressure; DBP, diastolic blood pressure.

aMultiple vessel disease included two and triple vessel disease and left main disease.

Table 4
Multiple binary logistic regression on risk of multiple vessel stenosis
dmj-35-248-i004.jpg

OR, odds ratio; CI, confidence interval; LDL, low density lipoprotein; CRP, C-reactive protein.

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • Adipokine chemerin overexpression in trophoblasts leads to dyslipidemia in pregnant mice: implications for preeclampsia
      Lunbo Tan, Zijun Ouyang, Zhilong Chen, Fen Sun, Haichun Guo, Feng Wang, Monique Mulder, Yuan Sun, Xifeng Lu, Jian V. Zhang, A. H. Jan Danser, Koen Verdonk, Xiujun Fan, Qing Yang
      Lipids in Health and Disease.2023;[Epub]     CrossRef
    • Chemerin Levels in Acute Coronary Syndrome: Systematic Review and Meta-Analysis
      Abdulrahman Ismaiel, Mohammad Zeeshan Ashfaq, Daniel-Corneliu Leucuta, Mohamed Ismaiel, Dilara Ensar Ismaiel, Stefan-Lucian Popa, Dan L Dumitrascu
      Laboratory Medicine.2022; 53(6): 552.     CrossRef
    • Prognostic value of plasma adipokine chemerin in patients with coronary artery disease
      Bo Wang, Wenxin Kou, Shuya Ji, Rongrong Shen, Hongwei Ji, Jianhui Zhuang, Yifan Zhao, Bo Li, Wenhui Peng, Xuejing Yu, Hailing Li, Yawei Xu
      Frontiers in Cardiovascular Medicine.2022;[Epub]     CrossRef
    • Role of Chemerin in Cardiovascular Diseases
      Mirjana T. Macvanin, Manfredi Rizzo, Jelena Radovanovic, Alper Sonmez, Francesco Paneni, Esma R. Isenovic
      Biomedicines.2022; 10(11): 2970.     CrossRef
    • Chemerin in inflammatory diseases
      Xin Su, Ye Cheng, Guoming Zhang, Bin Wang
      Clinica Chimica Acta.2021; 517: 41.     CrossRef
    • Chemerin activity in selected pathological states of human body – A systematic review
      Magdalena Acewicz, Irena Kasacka
      Advances in Medical Sciences.2021; 66(2): 270.     CrossRef
    • Chemerin in atherosclerosis
      Jia-Xiang Sun, Chi Zhang, Zhe-Bin Cheng, Mu-Yao Tang, Yi-Zhang Liu, Jie-Feng Jiang, Xuan Xiao, Liang Huang
      Clinica Chimica Acta.2021; 520: 8.     CrossRef
    • Serum Chemerin Concentration Is Associated with Proinflammatory Status in Chronic Coronary Syndrome
      Anna Szpakowicz, Malgorzata Szpakowicz, Magda Lapinska, Marlena Paniczko, Slawomir Lawicki, Andrzej Raczkowski, Marcin Kondraciuk, Emilia Sawicka, Malgorzata Chlabicz, Marcin Kozuch, Maciej Poludniewski, Slawomir Dobrzycki, Irina Kowalska, Karol Kaminski
      Biomolecules.2021; 11(8): 1149.     CrossRef
    • Novo Efeito Cardioprotetor da L-Carnitina em Camundongos Obesos Diabéticos: Regulação da Expressão de Quemerina e CMKLRI no Coração e Tecidos Adiposos
      Rezvan Amiri, Mohammad Reza Tabandeh, Seyed Ahmad Hosseini
      Arquivos Brasileiros de Cardiologia.2021; 117(4): 715.     CrossRef
    • The role of adipokines in the regulation of cardiovascular function
      A. V. Karpushev, V. B. Mikhailova
      "Arterial’naya Gipertenziya" ("Arterial Hypertension").2020; 25(5): 448.     CrossRef
    • The associations among RARRES2 rs17173608 gene polymorphism, serum chemerin, and non-traditional lipid profile in patients with metabolic syndrome
      Marwa A. Dahpy, Marwa K. Khairallah, Nashwa Mostafa A. Azoz, Ghada M. Ezzat
      Egyptian Journal of Medical Human Genetics.2020;[Epub]     CrossRef
    • Serum chemerin as a predictor of left ventricle hypertrophy in patients with coronary artery disease
      NohaHasssanin Hanboly, Yasser Sharaf, Mervat Al-Anany, Essam Saeed
      Nigerian Journal of Cardiology.2019; 16(1): 25.     CrossRef
    • Association of Circulating Chemerin With Subclinical Parameters of Atherosclerosis
      Stephanie Zylla, Marcus Dörr, Henry Völzke, Ulf Schminke, Stephan B. Felix, Matthias Nauck, Nele Friedrich
      Arteriosclerosis, Thrombosis, and Vascular Biology.2018; 38(7): 1656.     CrossRef
    • Six weeks of combined aerobic and resistance exercise using outdoor exercise machines improves fitness, insulin resistance, and chemerin in the Korean elderly: A pilot randomized controlled trial
      Dong-Il Kim, Dong Hoon Lee, Sunghyun Hong, Sung-won Jo, Young-shin Won, Justin Y. Jeon
      Archives of Gerontology and Geriatrics.2018; 75: 59.     CrossRef
    • Relationship between serum chemerin levels and insulin resistance index and cardio–respiratory function in non–active obese and lean men
      Mehdi Abbaszadegan, Farhad Kouhi achachluie
      Advances in Obesity, Weight Management & Control.2018;[Epub]     CrossRef
    • Serum levels of chemerin, apelin, vaspin, and omentin-1 in obese type 2 diabetic Egyptian patients with coronary artery stenosis
      Tarek M.K. Motawi, Soliman G. Mahdy, Maha M. El-Sawalhi, Eman N. Ali, Rania Farag A. El-Telbany
      Canadian Journal of Physiology and Pharmacology.2018; 96(1): 38.     CrossRef
    • Plasma CXCL1 levels and TRAF3IP2 variants in patients with myocardial infarction
      Safoora Pordel, Mahdi Sajedi Khanian, Mohammad Hossein Karimi, Hossein Nikoo, Mehrnoosh Doroudchi
      Journal of Clinical Laboratory Analysis.2018;[Epub]     CrossRef
    • Serum Chemerin Levels are Associated with Visceral Adiposity, Independent of Waist Circumference, in Newly Diagnosed Type 2 Diabetic Subjects
      Dae Young Cheon, Jun Goo Kang, Seong Jin Lee, Sung Hee Ihm, Eun Jig Lee, Moon Gi Choi, Hyung Joon Yoo, Chul Sik Kim
      Yonsei Medical Journal.2017; 58(2): 319.     CrossRef
    • The comparison of chemerin, adiponectin and lipid profile indices in obese and non-obese adolescents
      Zahra Maghsoudi, Roya Kelishadi, Mohammad Javad Hosseinzadeh-Attar
      Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2016; 10(2): S43.     CrossRef
    • Chemerin processing in the myocardium: A mechanism in search of a function
      Michael V.G. Latronico, Gianluigi Condorelli
      Journal of Molecular and Cellular Cardiology.2016; 100: 21.     CrossRef
    • Chemerin as an independent predictor of cardiovascular event risk
      Sinan İnci, Gökhan Aksan, Pınar Doğan
      Therapeutic Advances in Endocrinology and Metabolism.2016; 7(2): 57.     CrossRef
    • Chemerin level in pregnancies complicated by preeclampsia and its relation with disease severity and neonatal outcomes
      Orkun Cetin, Zehra Kurdoglu, Mertihan Kurdoglu, H. Guler Sahin
      Journal of Obstetrics and Gynaecology.2016; : 1.     CrossRef
    • Chemerin in renal dysfunction and cardiovascular disease
      Mario Bonomini, Assunta Pandolfi
      Vascular Pharmacology.2016; 77: 28.     CrossRef
    • High plasma chemerin is associated with renal dysfunction and predictive for cardiovascular events — Insights from phenotype and genotype characterization
      Andreas Leiherer, Axel Muendlein, Elena Kinz, Alexander Vonbank, Philipp Rein, Peter Fraunberger, Cornelia Malin, Christoph H. Saely, Heinz Drexel
      Vascular Pharmacology.2016; 77: 60.     CrossRef
    • Chemerin plays a protective role by regulating human umbilical vein endothelial cell-induced nitric oxide signaling in preeclampsia
      Liqiong Wang, Tianli Yang, Yiling Ding, Yan Zhong, Ling Yu, Mei Peng
      Endocrine.2015; 48(1): 299.     CrossRef
    • Evaluation of the salivary levels of visfatin, chemerin, and progranulin in periodontal inflammation
      Erkan Özcan, N. Işıl Saygun, Muhittin A. Serdar, Nezahat Kurt
      Clinical Oral Investigations.2015; 19(4): 921.     CrossRef
    • Elevated serum chemerin in Chinese women with hyperandrogenic PCOS
      LiQiong Wang, Yan Zhong, YiLing Ding, XiaoBo Shi, Jian Huang, FuFan Zhu
      Gynecological Endocrinology.2014; 30(10): 746.     CrossRef
    • Chemerin reduces vascular nitric oxide/cGMP signalling in rat aorta: a link to vascular dysfunction in obesity?
      Karla Bianca Neves, Núbia S. Lobato, Rhéure Alves Moreira Lopes, Fernando P. Filgueira, Camila Ziliotto Zanotto, Ana Maria Oliveira, Rita C. Tostes
      Clinical Science.2014; 127(2): 111.     CrossRef
    • Chemerin levels as predictor of acute coronary events: A case–control study nested within the veterans affairs normative aging study
      Konstantinos N. Aronis, Ayse Sahin-Efe, John P. Chamberland, Avron Spiro, Pantel Vokonas, Christos S. Mantzoros
      Metabolism.2014; 63(6): 760.     CrossRef
    • The predictive value of the first-trimester maternal serum chemerin level for pre-eclampsia
      Qiu-Lian Xu, Min Zhu, Yan Jin, Nan Wang, Hai-Xia Xu, Li-Mei Quan, Shan-Shan Wang, Shan-Shan Li
      Peptides.2014; 62: 150.     CrossRef
    • Evaluation of Circulating Adipokines and Abdominal Obesity as Predictors of Significant Myocardial Ischemia Using Gated Single-Photon Emission Computed Tomography
      Chi-Sheng Hung, Yen-Wen Wu, Jei-Yie Huang, Pei-Ying Hsu, Ming-Fong Chen, Xin-Liang Ma
      PLoS ONE.2014; 9(5): e97710.     CrossRef
    • Towards an integrative approach to understanding the role of chemerin in human health and disease
      J. L. Rourke, H. J. Dranse, C. J. Sinal
      Obesity Reviews.2013; 14(3): 245.     CrossRef
    • The association between chemerin and homeostasis assessment of insulin resistance at baseline and after weight reduction via lifestyle modifications in young obese adults
      Mi Kyung Lee, Sang Hui Chu, Duk Chul Lee, Ki Yong An, Ji-Hye Park, Dong Il Kim, Jiyoung Kim, Sunghyun Hong, Jee Aee Im, Ji Won Lee, Justin Y. Jeon
      Clinica Chimica Acta.2013; 421: 109.     CrossRef
    • Elevated Chemerin Levels in Pakistani Men: An Interrelation with Metabolic Syndrome Phenotypes
      Syeda Sadia Fatima, Kiymet Bozaoglu, Rehana Rehman, Faiza Alam, Abdul Shakoor Memon, Pascale Chavatte-Palmer
      PLoS ONE.2013; 8(2): e57113.     CrossRef
    • Chemerin: a potential endocrine link between obesity and type 2 diabetes
      Alexandra A. Roman, Sebastian D. Parlee, Christopher J. Sinal
      Endocrine.2012; 42(2): 243.     CrossRef
    • Elastase and Tryptase Govern TNFα-Mediated Production of Active Chemerin by Adipocytes
      Sebastian D. Parlee, Jenna O. McNeil, Shanmugam Muruganandan, Christopher J. Sinal, Kerry B. Goralski, Charaf Benarafa
      PLoS ONE.2012; 7(12): e51072.     CrossRef
    • Potential association between coronary artery disease and the inflammatory biomarker YKL-40 in asymptomatic patients with type 2 diabetes mellitus
      Hyun Min Kim, Byung-Wan Lee, Young-Mi Song, Won Jin Kim, Hyuk-Jae Chang, Dong-Hoon Choi, Hee Tae Yu, EunSeok Kang, Bong Soo Cha, Hyun Chul Lee
      Cardiovascular Diabetology.2012;[Epub]     CrossRef
    • The association of serum chemerin level with risk of coronary artery disease in Chinese adults
      Qun Yan, Yifei Zhang, Jie Hong, Weiqiong Gu, Meng Dai, Juan Shi, Ying Zhai, Weiqing Wang, Xiaoying Li, Guang Ning
      Endocrine.2012; 41(2): 281.     CrossRef
    • Epidemiology of Micro- and Macrovascular Complications of Type 2 Diabetes in Korea
      Jung Hee Kim, Dae Jung Kim, Hak Chul Jang, Sung Hee Choi
      Diabetes & Metabolism Journal.2011; 35(6): 571.     CrossRef
    • Chemerin: A Novel Link between Inflammation and Atherosclerosis?
      Eun-Jung Rhee
      Diabetes & Metabolism Journal.2011; 35(3): 216.     CrossRef

    • PubReader PubReader
    • Cite
      CITE
      export Copy
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Relationship between Chemerin Levels and Cardiometabolic Parameters and Degree of Coronary Stenosis in Korean Patients with Coronary Artery Disease
      Diabetes Metab J. 2011;35(3):248-254.   Published online June 30, 2011
      Close
    • XML DownloadXML Download
    Figure

    Diabetes Metab J : Diabetes & Metabolism Journal